Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Depressant+1 more
Sodium channel blockerDextropropoxyphene
Dextropropoxyphene (propoxyphene) — sold as Darvon — is a synthetic opioid of the diphenylpropylamine class. It is a structural relative of methadone, but with far weaker analgesic potency and a narrow margin between a therapeutic and a dangerous dose. It activates opioid receptors in the brain, suppressing pain signals and producing mild sedation.
Dextropropoxyphene (propoxyphene) — Darvon — is a synthetic opioid of the diphenylpropylamine class. It is a structural relative of methadone, distinguished by far weaker analgesic potency and a narrow therapeutic index. Dextropropoxyphene is a mu-opioid receptor agonist with unusually low binding affinity,[1] producing its effects through opioid-mediated pain suppression and sedation.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Depressant+1 more
Sodium channel blockerSynthesized at Eli Lilly in 1953[1] and marketed from 1957 as Darvon, it became one of the most widely prescribed analgesics in the English-speaking world despite evidence it worked no better than paracetamol.[2] Overdose deaths far out of proportion to its modest benefit led regulators to act. It was withdrawn from US, UK, EU, and Australian markets between 2005 and 2010.
Subjective effects include mild pain suppression, gentle warmth, light sedation, and a quiet easing of anxiety. The experience is that of a weak, short-lived opioid — modest comfort without the heavy drowsiness or depth of stronger compounds. Nausea, dizziness, and constipation are common unwanted effects.
Dextropropoxyphene produces moderate physical and psychological dependence,[3] and fatal overdose can occur within an hour at doses only slightly above the therapeutic range.[4] A cardiotoxic metabolite — norpropoxyphene — blocks the heart's electrical signaling in a way naloxone cannot reverse, making standard opioid overdose protocols insufficient.[5] Six decades of clinical and forensic data underpin the risk profile, though no formal human LD₅₀ has been published.
History[edit]
Discovery
Dextropropoxyphene was synthesized by A. Pohland and H.R. Sullivan at Eli Lilly in 1953.[1] It was designed as a milder version of methadone — same structural backbone, lower expected abuse liability. US Patent No. 2,728,779 was granted to Eli Lilly in 1955.[6]
Prescribing era and overdose crisis
The drug reached the US market in 1957 as Darvon,[7] promoted as safer than codeine. Combination products followed — Darvocet in the US and co-proxamol (Distalgesic) in the UK. By the 1970s it ranked among the most prescribed analgesics in both countries, despite forensic evidence that overdose deaths were disproportionate to its modest clinical benefit.
Withdrawal
The UK withdrew co-proxamol in January 2005,[8] the EU followed in 2008, and the US FDA requested voluntary market withdrawal in November 2010 citing cardiac abnormalities at therapeutic doses.[9] Australia removed it from its therapeutic register around the same time. The UK withdrawal is estimated to have prevented 300–400 overdose deaths per year in England and Wales.[10]
The brand name Darvon became synonymous in American culture with casual prescription painkiller use during the 1970s and 1980s. Co-proxamol acquired a grimmer reputation in British forensic medicine — coroners in the West Midlands identified Distalgesic as the single most common cause of fatal drug overdose in their region,[4] and its role in completed suicides made it a defining case study in means restriction as a public health tool.
Chemistry[edit]
Structural class
Dextropropoxyphene belongs to the diphenylpropylamine family of synthetic opioids — the same structural lineage as methadone. Its molecular formula is C₂₂H₂₉NO₂ (molecular weight 339.5 g/mol). A propanoate ester group — in place of the ketone found in methadone — contributes to its weaker receptor binding.
Stereochemistry
The molecule exists in two mirror-image forms. Only the dextropropoxyphene form produces analgesia; its mirror image, levopropoxyphene, has only a cough-suppressant effect.[6] Two pharmaceutical salt forms were marketed: propoxyphene hydrochloride (65 mg capsules) and propoxyphene napsylate (100 mg tablets). A 100 mg napsylate dose is equivalent in analgesic effect to 65 mg hydrochloride[7] — the two salts are not interchangeable by weight.
Pharmacology[edit]
Mechanism of action
Dextropropoxyphene activates mu-opioid receptors with unusually low binding affinity — among the weakest of any approved opioid.[11] Despite this, it behaves differently from morphine: animals tolerant to morphine's pain-relieving effects retain full sensitivity to dextropropoxyphene,[12] suggesting it engages slightly different signaling pathways.
Two separate cardiac effects can prove fatal — neither reversed by naloxone. The parent compound blocks sodium channels in the heart, slowing electrical conduction and widening the QRS complex.[13] The metabolite norpropoxyphene blocks potassium channels responsible for resetting the heart's rhythm after each beat, risking fatal irregular rhythms.[5]
Pharmacokinetics
The liver converts dextropropoxyphene to norpropoxyphene via CYP3A4.[14] Norpropoxyphene has a half-life of 30–36 hours — up to 76 hours in elderly patients[15] — so it accumulates significantly with repeated dosing. Genetic variation in CYP3A5 can raise peak drug levels by 75–83% at the same dose,[16] which helps explain why toxicity is unpredictable across individuals.
Neuroscience[edit]
Where it acts
Dextropropoxyphene activates the brain's mesolimbic pathway by freeing dopamine in the nucleus accumbens.[7] Pain relief occurs through a separate descending pathway from brain to spinal cord. Systematic reviews found its pain-relieving effect equivalent to paracetamol alone,[2] suggesting limited functional engagement of this pathway at therapeutic doses.
Why it matters
The drug's paradox: abuse potential that exceeds what its weak analgesia would predict. It appears to engage the brain's pleasure signal more readily than its motivational drive — producing a modest hedonic effect that fades quickly, which may explain the compulsive redosing pattern seen in dependence.[3]
Whether dextropropoxyphene's sodium channel effects contribute independently to analgesia remains untested.[13] Its differential tolerance profile compared to morphine[12] suggests engagement of distinct receptor populations, but this has not been characterized at the molecular level. The weak serotonin reuptake activity[17] raises unanswered questions about whether serotonergic tone shapes the warmth and anxiolysis users report.
Subjective Effects[edit]
Dextropropoxyphene produces a subdued opioid experience — gentle warmth, light physical sedation, and a quiet narrowing of mental activity. It is defined more by what it removes than what it adds: a lowering of pain and anxiety rather than any pronounced euphoria or depth.
Compared to codeine, it is milder and less reliably analgesic. Alongside tramadol, it sits in a similar tier among the weakest clinical opioids. Its defining characteristic is not what it offers experientially but what it costs — a disproportionate toxicity profile relative to its modest subjective effects.[2]
Synthesized at Eli Lilly in 1953[2] and marketed from 1957 as Darvon, dextropropoxyphene became one of the most widely prescribed analgesics in the English-speaking world despite systematic reviews finding its efficacy equivalent to paracetamol alone.[3] Regulatory authorities in the UK, EU, US, and Australia withdrew the drug between 2005 and 2010 after forensic evidence revealed disproportionate overdose fatalities.
Subjective effects include mild analgesia, warmth, anxiolysis, and light sedation. The experience is that of a gentle, short-lived opioid — modest euphoria without the pronounced nod or depth of stronger compounds. Nausea, dizziness, and constipation are characteristic unsought effects.
Dextropropoxyphene produces moderate physical and psychological dependence,[4] and fatal overdose can occur within one hour of ingestion at doses as low as fifteen co-proxamol tablets.[5] Its cardiotoxic metabolite norpropoxyphene blocks cardiac ion channels through mechanisms that naloxone cannot reverse, meaning standard opioid overdose protocols are insufficient.[6] Six decades of clinical and forensic data underpin the current understanding, though no formal human bioavailability or LD₅₀ values have been published.
History[edit]
Discovery
Dextropropoxyphene was synthesized by A. Pohland and H.R. Sullivan at Eli Lilly and Company in 1953.[2] The compound was designed as a milder structural relative of methadone — sharing the diphenylpropylamine backbone but intended to produce weaker analgesia with lower abuse liability. The dextrorotatory enantiomer was identified as the pharmacologically active analgesic form, and US Patent No. 2,728,779 was granted to Eli Lilly in 1955.[7]
Prescribing era and overdose crisis
Dextropropoxyphene entered the US market in 1957 as Darvon,[8] promoted as a synthetic analgesic with lower addiction potential than codeine — a claim that decades of pharmacovigilance would discredit. Combination products followed: Darvocet (with paracetamol) in the US, and co-proxamol (Distalgesic) in the UK. By the 1970s, propoxyphene-containing products ranked among the most frequently prescribed analgesics in both countries, despite accumulating evidence that the drug caused disproportionate overdose deaths relative to its modest therapeutic benefit.
Withdrawal
The UK Committee on Safety of Medicines announced withdrawal of co-proxamol in January 2005,[9] and the European Medicines Agency recommended EU-wide withdrawal in 2008. The US FDA requested voluntary market withdrawal in November 2010, citing cardiac conduction abnormalities at therapeutic doses.[10] Australia cancelled dextropropoxyphene from its register around the same time. Six-year follow-up estimated the UK withdrawal prevented 300–400 overdose deaths per year in England and Wales, with no evidence of substitution to equally lethal methods.[11]
The name "propoxyphene" derives from its propanoate ester and diphenyl structure. The brand name Darvon became synonymous in American culture with prescription painkiller overuse during the 1970s and 1980s, referenced in popular media as a symbol of casual pill-taking. Co-proxamol acquired a grimmer reputation in British forensic medicine — coroners in the West Midlands identified Distalgesic as the single most common cause of fatal drug overdose in their region,[5] and the drug's role in completed suicides made it a defining case study in means restriction as public health intervention.
Chemistry[edit]
Structural class
Dextropropoxyphene belongs to the diphenylpropylamine family of synthetic opioids — the same structural lineage as methadone. The molecule carries two phenyl rings bonded to a central carbon, a propanoate ester linkage (replacing the ketone found in methadone), and a dimethylamino group conferring basicity. The ester substitution contributes directly to its weaker opioid receptor binding relative to methadone.
Molecular structure
| Molecular formula | C₂₂H₂₉NO₂ |
| Molecular weight | 339.5 g/mol |
The propanoate ester provides a hydrolyzable site susceptible to metabolic cleavage — a property exploited in hepatic first-pass metabolism. The dimethylaminomethyl group gives the molecule a pKa of approximately 6.3.
Stereochemistry
Propoxyphene has two chirality centers, yielding four possible stereoisomers. Dextropropoxyphene is the (2S,3R)-enantiomer — the dextrorotatory form responsible for analgesic activity. Its mirror image, levopropoxyphene (2R,3S), retains antitussive properties but lacks meaningful analgesia.[7] This stereospecificity is consistent with the well-established chiral selectivity of μ-opioid binding.
Two pharmaceutical salt forms were marketed: propoxyphene hydrochloride (65 mg capsules) and propoxyphene napsylate (100 mg tablets). The napsylate salt — a naphthalene-2-sulfonate — was designed for slower absorption. A 100 mg napsylate dose provides analgesic equivalence to 65 mg hydrochloride.[8]
Physical properties
Dextropropoxyphene free base is a white crystalline powder with very low water solubility (~0.02 mg/mL).[12] The hydrochloride salt form has improved aqueous solubility suitable for oral formulation. The propanoate ester is susceptible to hydrolysis under acidic or enzymatic conditions.
Pharmacology[edit]
Mechanism of action
Dextropropoxyphene activates mu-opioid receptors with unusually low binding affinity — ranked in the weakest tier among approved opioids, alongside tramadol and codeine.[1] Despite this weak binding, its receptor behavior differs from morphine in important ways: morphine-tolerant animals retain full sensitivity to dextropropoxyphene's pain-relieving effects, indicating engagement of partially distinct signaling pathways.[13]
Beyond opioid activity, the parent compound blocks sodium channels in a use-dependent manner, with recovery roughly ten times slower than lidocaine.[14] This produces the widened QRS complex seen on ECG in overdose. The primary metabolite, norpropoxyphene, blocks HERG potassium channels responsible for cardiac repolarization[6] — a second cardiotoxic mechanism entirely independent of opioid effects and unresponsive to naloxone.
Dextropropoxyphene also exhibits weak serotonin reuptake inhibition, placing it among opioids (alongside meperidine, tramadol, and methadone) that can trigger serotonin syndrome when combined with monoamine oxidase inhibitors.[15]
Pharmacokinetics
Administered orally, dextropropoxyphene undergoes extensive first-pass metabolism in the liver. Peak plasma concentrations occur within 1–2 hours of dosing.[16] No published study has measured oral bioavailability in humans. Distribution is extensive (volume of distribution ~12 L/kg) with 76–80% plasma protein binding.[12]
The liver converts dextropropoxyphene to norpropoxyphene primarily via CYP3A4.[17] Norpropoxyphene lacks analgesic activity but is cardiotoxic. Its half-life of 30–36 hours means it accumulates substantially with repeated dosing — and in elderly patients, half-lives extend to 53 hours on average, up to 76 hours.[18]
Genetic variation in CYP3A5 significantly affects drug exposure: individuals carrying the CYP3A5*3/*3 genotype experience approximately 75–83% higher peak plasma levels at any given dose.[19] This pharmacogenomic variability explains part of the unpredictable toxicity profile across individuals.
Norpropoxyphene accumulates dangerously in kidney failure, making dextropropoxyphene contraindicated in chronic renal disease.[20]
Neuroscience[edit]
Where it acts
Dextropropoxyphene engages the mesolimbic mesolimbic pathway through mu-opioid receptors in the ventral tegmental area, disinhibiting dopamine release into the nucleus accumbens. Its documented euphorigenic properties and abuse potential[8] confirm functional activation of this circuit despite weak receptor affinity. Pain modulation occurs through the standard descending pathway (periaqueductal gray to spinal dorsal horn), though systematic reviews finding efficacy equivalent to paracetamol alone[3] suggest minimal functional engagement at therapeutic doses.
Why it matters
The incentive salience framework helps explain dextropropoxyphene's paradox: abuse potential exceeding what its weak analgesic efficacy would predict. The drug appears to preferentially engage the hedonic "liking" system (mu-opioid signaling in nucleus accumbens) relative to the dopaminergic "wanting" circuit — producing subjective pleasure without proportional motivational drive. This may explain the compulsive redosing pattern observed in dependence[4]: users chase a modest hedonic signal that dissipates quickly.
The differential tolerance profile between dextropropoxyphene and morphine[13] strongly suggests engagement of distinct receptor populations or splice variants, but no study has characterized this at the molecular level. Whether the drug's sodium channel blockade at neuronal subtypes contributes to analgesia independently of opioid activity remains untested.[14] The weak serotonin reuptake activity[15] raises unanswered questions about whether serotonergic tone contributes to the warmth and anxiolysis users report, or whether these are purely opioid-mediated.
Subjective Effects[edit]
Dextropropoxyphene produces a subdued opioid experience — gentle warmth, light physical sedation, and a quiet narrowing of mental activity rather than the heavy nod or pronounced euphoria of stronger compounds. At low therapeutic doses the effect is barely distinguishable from paracetamol;[3] at higher doses the opioid character emerges more clearly, though CYP3A5 pharmacogenomic variation can nearly double effective exposure at identical doses,[19] making the dose-response curve unpredictable between individuals.
Compared to codeine, dextropropoxyphene is milder and less clearly analgesic. Compared to tramadol, it lacks the dual opioid-monoaminergic character but shares a comparable position among the weakest clinical opioids. Its defining distinction is not what it offers experientially but what it costs — a disproportionate toxicity profile relative to its modest subjective effects.
Effect Grid
At 65–100 mg oral (the standard therapeutic dose range as hydrochloride salt), moderate opioid warmth, sedation, and mild cognitive euphoria are present. Anxiety suppression is noticeable. Thought deceleration and emotional suppression create a sense of mental quieting. Some users report a modest tactile euphoria — a diffuse bodily comfort characteristic of weak opioid agonism.
Nausea, constipation, and dizziness are common at this tier. Pupil constriction (miosis) is observable. Respiratory depression is present but subclinical in healthy individuals at this dose. Dry mouth may occur due to mild anticholinergic activity.
The analgesic effect peaks at this tier but remains equivalent to paracetamol alone. Norpropoxyphene (half-life 30–36 hours) begins accumulating with repeated dosing, introducing cardiac risk independent of subjective tolerance.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Breathing alteration · Constipation · Muscle relaxation · Bodily heaviness · Body high · Dizziness · Nausea · Physical fatigue · Tactile euphoria · Abnormal heartbeat · Dry mouth · Excessive sweating · Headache · Vomiting · Yawning · Seizure threshold reduction
Bodily heaviness · Body high · Dizziness · Nausea · Physical fatigue · Tactile euphoria · Dry mouth · Excessive sweating · Headache · Vomiting · Yawning · Seizure threshold reduction
Information processing suppression · Cognitive euphoria · Confusion · Thought deceleration · Delusions of sobriety · Delirium
Thought deceleration · Delirium
Timeline
Initial warmth and mild anxiolysis as plasma concentrations rise. Subtle bodily relaxation begins within 20–30 minutes of oral ingestion.
Maximum opioid effects — sedation, cognitive euphoria, pain suppression, miosis. Corresponds to Tmax of 1–2 hours with sustained effects through 4 hours at standard doses.
Gradual decline of subjective effects with residual sedation and possible nausea. Norpropoxyphene continues to accumulate systemically with a 30–36 hour half-life, maintaining cardiac risk beyond subjective awareness.
⚠ Avoid driving or operating machinery for at least 6 hours after dosing — residual sedation and impaired reaction time may persist beyond subjective awareness of effects.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- High
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 1.5 weeks
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- opioids
Toxicity
Acute overdose
Fatal overdose occurs rapidly. Death within one hour of ingestion has been documented repeatedly, often before medical intervention is possible.[4][18][19] The fatal dose can be as low as approximately fifteen co-proxamol tablets, and alcohol lowers this threshold further.[4]
Overdose presents with coma, stopped or severely slowed breathing, vomiting, seizures, and cardiovascular collapse. No formal human LD₅₀ has been published.safety citation needed
Heart toxicity
Two distinct cardiac mechanisms drive toxicity — neither reversed by naloxone:
- Sodium channel blockade by the parent compound causes progressive widening of the QRS complex, with recovery roughly ten times slower than lidocaine[13]
- Potassium channel blockade by norpropoxyphene prolongs the QT interval, risking fatal irregular heart rhythms[5]
Norpropoxyphene's half-life of 30–36 hours (up to 76 hours in elderly patients[15]) means cardiac risk persists long after breathing has been stabilized. The FDA cited cardiac abnormalities at recommended therapeutic doses as grounds for withdrawal.[9]
Alcohol synergism
Alcohol dramatically amplifies toxicity. Blood concentrations survivable alone become fatal with co-ingestion.[20][21] Middle-aged men faced the highest risk of non-suicidal dextropropoxyphene-alcohol death.[22]
Kidney failure
Norpropoxyphene accumulates to toxic levels in kidney failure. Dextropropoxyphene is contraindicated in chronic kidney disease.[23]
Public health impact
Co-proxamol accounted for 18% of drug-related suicides in England and Wales during 1997–1999, representing 5% of all suicides nationally.[19] In Sweden it was the most common drug found in fatal self-inflicted poisoning.[24] The UK withdrawal reduced estimated overdose deaths by 300–400 per year.[10]
Psychological risks
Confusion and cognitive impairment occur in elderly patients at therapeutic doses, driven by drug accumulation at dramatically prolonged half-lives.[15] Hallucinations have been reported as an adverse effect.[25]
The primary psychological risk is contribution to completed suicide — driven by rapid lethality in overdose, ease of access, and availability in quantities sufficient for self-harm.[19][26]
Tolerance & dependence
Tolerance to analgesic and euphoric effects develops with repeated use.[3] Cross-tolerance with morphine appears incomplete.[12]
A critical hazard: norpropoxyphene accumulates independently of opioid tolerance. The cardiac risk does not plateau as subjective tolerance grows — increasing the dose to chase the same effect raises cardiac danger without warning. Both physical and psychological dependence are documented, and abuse potential was consistently underestimated during the prescribing era.[7]
Drug Interactions
Lethal combinations
Alcohol is the best-documented lethal combination: concentrations survivable alone become fatal with co-ingestion.[20][21] Benzodiazepines, other opioids, GHB/GBL, and ketamine add to respiratory and cardiovascular depression.safety citation needed
Enzyme inhibition
Dextropropoxyphene potently inhibits CYP2D6,[7] raising blood levels of drugs cleared by this enzyme:
- Metoprolol: life-threatening heart rate of ~30 bpm has been documented[27]
- Carbamazepine: elevated levels risking toxicity[28]
- Tricyclic antidepressants: elevated levels with additive cardiac toxicity risk
- Warfarin: enhanced blood-thinning effect
- Alprazolam: impaired clearance[29]
Serotonin toxicity
Combining with monoamine oxidase inhibitors (phenelzine, tranylcypromine, linezolid, moclobemide) can trigger dangerous serotonin overload — an overheating and seizure response that can be fatal.[17]
Contraindications
10 knownAbsolute
- Alcohol or CNS depressants (benzodiazepines, other opioids, GHB/GBL, barbiturates): synergistic respiratory and cardiac depression; alcohol lowers the fatal dose to otherwise survivable levels[20]
- Monoamine oxidase inhibitors: risk of fatal serotonin syndrome[17]
- Chronic kidney failure: norpropoxyphene accumulates to toxic concentrations[23]
- Pre-existing heart conduction abnormalities (prolonged QTc, bundle branch block, arrhythmia history): propoxyphene and norpropoxyphene worsen both sodium and potassium channel dysfunction[5][13]
Relative
- Elderly patients: half-life 5–10 times longer than in younger adults produces dangerous accumulation[15]
- Liver impairment: reduced clearance alters the parent-to-metabolite ratio[25]
- Respiratory disease (COPD, sleep apnea): opioid respiratory depression compounds existing breathing problems
- QT-prolonging medications (antipsychotics, certain antibiotics, class III antiarrhythmics): additive QT risk via norpropoxyphene[5]
- CYP2D6 substrate medications (metoprolol, tricyclic antidepressants): enzyme inhibition raises co-administered drug levels[27]
- CYP3A5 poor expressers (CYP3A5*3/*3 genotype): approximately 75–83% higher drug exposure at any given dose[16]
Harm Reduction[edit]
Forms & Identification
Dextropropoxyphene has been withdrawn from all major pharmaceutical markets. Any product encountered today is either diverted legacy stock or sourced from unregulated markets in jurisdictions where withdrawal was not enforced.
Old stock may have degraded unpredictably — the propanoate ester is susceptible to hydrolysis, altering both potency and impurity profile.
The two salt forms are not interchangeable by weight: 100 mg napsylate equals 65 mg hydrochloride in analgesic effect.[7] Confusing the two salts can cause unintentional overdose. Authentic pharmaceutical forms were always oral tablets or capsules — no injection or insufflation formulation ever existed.
Guidelines
- Never combine with alcohol under any circumstances — doses survivable alone become fatal with co-ingestion[20]
- Never exceed the therapeutic dose range (65 mg hydrochloride / 100 mg napsylate per dose)
- Allow minimum 4–6 hours between doses to avoid norpropoxyphene accumulation
- Ensure someone present knows what was taken, when, and how much
- Do not use if taking MAOIs, benzodiazepines, other opioids, or any QT-prolonging medication
- Individuals of unknown CYP3A5 genotype should assume higher sensitivity — start at the lowest effective dose[16]
- Never redose based on perceived tolerance — cardiotoxic metabolite accumulation proceeds independently of subjective opioid tolerance
Set & Setting
The primary risk is physiological collapse — cardiac arrest or respiratory failure occurring within one hour of an excessive dose.[4]
Never use alone. A sober observer who knows what was taken and can call emergency services is the single most important harm reduction measure for this substance.
Aftercare & integration. Norpropoxyphene persists in the body for 30–36 hours after the last dose (longer in older adults). Cardiac vulnerability continues during this period even after subjective effects have resolved. Avoid alcohol, other depressants, and physical exertion for at least 48 hours after the last dose.
If repeated use has occurred, monitor for early withdrawal signs — anxiety, insomnia, muscle aches, gut distress — beginning 12–24 hours after the last dose. These are manageable but indicate developing dependence.
Recovery & Support
Physical withdrawal peaks within 48–72 hours and resolves over 7–14 days, but psychological craving and disrupted sleep may persist for weeks. Medical supervision during withdrawal is recommended — accumulated norpropoxyphene creates cardiac risk in the early withdrawal period.
Opioid-specific resources include SMART Recovery, Narcotics Anonymous, and medically assisted treatment programs. Since dextropropoxyphene is no longer marketed, dependence today involves diverted or legacy supplies — disclosing this to a healthcare provider allows appropriate management without the complications of ongoing prescribing.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Blue or grey lips, slowed or stopped breathing, unresponsiveness, seizures, or collapse within minutes to one hour of ingestion. Unlike most opioid overdoses, cardiac arrest is a primary risk — the person may have a pulse but develop a fatal irregular heart rhythm.
Immediate steps:
- 1. Call emergency services immediately — do not wait to see if they recover
- 2. Administer naloxone if available — it reverses respiratory depression but does NOT reverse cardiac toxicity[5]
- 3. Place in recovery position if breathing but unconscious
- 4. Begin CPR if no pulse or no breathing
- 5. Do NOT induce vomiting
What to tell the dispatcher: Name the substance (propoxyphene/Darvon/co-proxamol), approximate amount taken, time of ingestion, whether alcohol was involved, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from prosecution.
Reversal agents: Naloxone reverses opioid respiratory depression but has no effect on propoxyphene/norpropoxyphene cardiac toxicity.[5] Cardiac toxicity requires hospital-level intervention — sodium bicarbonate for QRS widening, magnesium for QT prolongation. Hospital transport is essential even after naloxone administration.
Legal Status[edit]
Dextropropoxyphene has been withdrawn from pharmaceutical markets in all major jurisdictions.
| Jurisdiction | Status | Key provisions |
|---|---|---|
| United States | Withdrawn (November 19, 2010) | FDA requested voluntary market withdrawal citing QT prolongation at therapeutic doses; formerly DEA Schedule IV[9][30] |
| United Kingdom | Withdrawn (2005–2008) | CSM announced withdrawal January 2005; phased removal complete by 2008. Estimated 300–400 fewer overdose deaths per year[10] |
| European Union | Withdrawn (2008) | EMA recommended withdrawal of all marketing authorisations across member states |
| Ireland | Withdrawn (January 2006) | Distalgesic removed from Irish market[31] |
| Scotland | Withdrawn (2005–2008) | Followed UK CSM guidance; measurable reduction in poisoning deaths[32] |
| Australia | Cancelled from ARTG (~2010) | Dextropropoxyphene-containing products cancelled from Australian Register of Therapeutic Goods |
| India | Banned (2013) | Fixed-dose combinations banned by CDSCO |
| Canada | Status not confirmed | Regulatory status not verified in sources reviewedcitation needed |
Legal status changes frequently and varies by jurisdiction. This information reflects sources reviewed at time of writing and is not legal advice.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- High
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 1.5 weeks
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- opioids
Toxicity
Dextropropoxyphene carries high acute toxicity and a narrow therapeutic index — among the most dangerous weak opioids ever marketed.
Acute overdose
Fatal overdose occurs rapidly. Death within one hour of ingestion has been repeatedly documented, often before medical intervention is possible.[5][21][22] The fatal dose can be as low as approximately 490 mg (fifteen co-proxamol tablets), with the threshold lowered further by alcohol.[5] No formal human LD₅₀ has been published.safety citation needed
Overdose presents with coma, respiratory depression, vomiting, seizures, circulatory collapse, and constricted pupils.
Heart toxicity
Two distinct mechanisms drive cardiac toxicity, neither reversed by naloxone:
- Sodium channel blockade by the parent compound causes progressive widening of the QRS complex, with recovery roughly ten times slower than lidocaine[14]
- Potassium channel blockade by norpropoxyphene causes dangerous prolongation of the QT interval, risking fatal irregular heart rhythms[6]
Norpropoxyphene's long half-life (30–36 hours, up to 76 hours in elderly patients[18]) means cardiac risk persists long after breathing problems have been treated. The FDA cited cardiac abnormalities at recommended therapeutic doses as grounds for withdrawal.[10]
Alcohol synergism
Alcohol profoundly worsens dextropropoxyphene toxicity. Finnish forensic data showed that blood concentrations of propoxyphene in fatal alcohol-combined poisonings were significantly lower than in pure-drug fatalities — confirming that doses survivable alone become lethal with alcohol.[23][24] Middle-aged men were at highest risk for non-suicidal dextropropoxyphene-alcohol death.[25]
Kidney failure
Norpropoxyphene accumulates to toxic levels in kidney failure. Dextropropoxyphene is contraindicated in chronic kidney disease.[20]
Public health impact
Co-proxamol accounted for 18% of drug-related suicides in England and Wales during 1997–1999, representing 5% of all suicides nationally.[22] In Sweden, dextropropoxyphene was the most common drug in self-inflicted fatal poisoning.[26] The UK withdrawal was followed by an estimated 300–400 fewer overdose deaths per year.[11]
Psychological risks
Confusion and cognitive impairment occur in elderly patients at therapeutic doses due to drug and metabolite accumulation at dramatically prolonged half-lives.[18] Hallucinations have been reported as an adverse effect.[27] In overdose, delirium and seizures occur.
The primary psychological risk lies in the drug's contribution to completed suicide — driven by accessibility, rapid lethality in overdose, and availability in quantities sufficient for self-harm.[22][28]
Tolerance & dependence
Tolerance to analgesic and euphoric effects develops with repeated use, consistent with μ-opioid pharmacology.[4] Cross-tolerance with morphine appears incomplete or asymmetric based on animal data.[13]
A critical hazard during tolerance development: the cardiotoxic metabolite norpropoxyphene accumulates independently of opioid tolerance. The dose at which cardiac risk becomes significant does not parallel the dose at which subjective tolerance is perceived.
Both physical and psychological dependence are documented at moderate severity.[4] Withdrawal symptoms resemble the classical opioid pattern: anxiety, insomnia, muscle pain, gut distress, and craving. Abuse potential was consistently underestimated during the prescribing era.[8] At maximum tolerated doses, propoxyphene napsylate produces subjective effects equivalent to 20–25 mg/day subcutaneous morphine.[29]
Drug Interactions
Lethal combinations
Alcohol is the best-documented lethal combination: blood concentrations survivable alone become fatal with co-ingestion.[23][24] Benzodiazepines, other opioids, GHB/GBL, and ketamine produce additive or synergistic respiratory and cardiovascular depression.safety citation needed
Enzyme inhibition
Dextropropoxyphene potently inhibits CYP2D6,[8] elevating blood levels of co-administered drugs metabolized by this enzyme:
- Metoprolol: life-threatening slow heart rate (~30 bpm) has been documented[30]
- Carbamazepine: elevated levels risking carbamazepine toxicity[31]
- Tricyclic antidepressants: elevated levels with additive cardiac toxicity risk
- Warfarin: enhanced blood-thinning effect
- Alprazolam: impaired clearance[32]
Serotonin toxicity
Dextropropoxyphene's weak serotonin reuptake inhibitor makes it dangerous with monoamine oxidase inhibitors (phenelzine, tranylcypromine, linezolid, moclobemide). Fatalities from serotonin syndrome have occurred with structurally related opioid/MAOI combinations.[15]
Contraindications
10 knownAbsolute
- Concurrent alcohol or CNS depressants (benzodiazepines, other opioids, GHB/GBL, barbiturates): synergistic respiratory depression and cardiac toxicity; alcohol lowers the fatal dose to otherwise survivable levels[23]
- Monoamine oxidase inhibitors: risk of fatal serotonin toxicity[15]
- Chronic kidney failure: norpropoxyphene accumulates to toxic concentrations[20]
- Pre-existing heart conduction abnormalities (prolonged QTc, bundle branch block, arrhythmia history): propoxyphene and norpropoxyphene worsen sodium and potassium channel dysfunction[6][14]
Relative
- Elderly patients: half-life prolongation of 5–10 times younger-adult values produces dangerous accumulation[18]
- Liver impairment: reduced clearance alters parent-to-metabolite ratio[27]
- Respiratory disease (COPD, sleep apnea): opioid respiratory depression compounds existing breathing problems
- QT-prolonging medications (antipsychotics, certain antibiotics, class III antiarrhythmics): additive QT risk via norpropoxyphene[6]
- CYP2D6 substrate medications (metoprolol, tricyclic antidepressants): propoxyphene's enzyme inhibition raises co-administered drug levels[30]
- CYP3A5 poor expressers (CYP3A5*3/*3 genotype): approximately 75–83% higher drug exposure at any given dose[19]
Harm Reduction[edit]
Forms & Identification
Dextropropoxyphene has been withdrawn from all major pharmaceutical markets. Any product encountered today is either diverted legacy stock (potentially degraded) or sourced from unregulated markets in jurisdictions where withdrawal was not enforced. The propanoate ester in the molecule is susceptible to hydrolysis — old stock may have degraded unpredictably, altering both potency and impurity profile.
Authentic pharmaceutical forms were always oral tablets or capsules. The two salt forms (hydrochloride 65 mg capsules, napsylate 100 mg tablets) are not interchangeable by weight — 100 mg napsylate equals 65 mg hydrochloride in analgesic effect.[8] Confusing the two salts can produce unintentional overdose.
Guidelines
- Never combine with alcohol under any circumstances — doses survivable alone become fatal with co-ingestion[23]
- Never exceed the therapeutic dose range (65 mg hydrochloride / 100 mg napsylate per dose)
- Allow minimum 4–6 hours between doses to avoid norpropoxyphene accumulation
- Ensure someone present knows what was taken, when, and how much
- Do not use if taking MAOIs, benzodiazepines, other opioids, or any QT-prolonging medication
- Individuals of unknown CYP3A5 genotype should assume higher sensitivity — start at the lowest effective dose[19]
- Never redose based on perceived tolerance — cardiotoxic metabolite accumulation proceeds independently of subjective opioid tolerance
Set & Setting
Given dextropropoxyphene's narrow therapeutic index and rapid lethality in overdose, context is unusually safety-critical. The primary risk is not psychological distress but physiological collapse — cardiac arrest or respiratory failure occurring within one hour of an excessive dose.[5]
Use should never occur alone. A sober observer who knows what was taken and can call emergency services is the single most important harm reduction measure for this substance.
Aftercare & integration. Following dextropropoxyphene use, norpropoxyphene persists in the body for 30–36 hours (longer in older adults). During this period, cardiac vulnerability continues even as subjective effects have resolved. Avoid alcohol, other depressants, and physical exertion for at least 48 hours after the last dose.
If repeated use has occurred, monitor for early withdrawal signs (anxiety, insomnia, muscle aches, gut distress) beginning 12–24 hours after the last dose. These are manageable but indicate developing dependence.
Recovery & Support
Dextropropoxyphene dependence follows the standard opioid pattern: physical withdrawal peaks within 48–72 hours and resolves over 7–14 days, but psychological craving and sleep disruption may persist for weeks. Medical supervision for withdrawal is recommended — particularly because the cardiac toxicity risk from accumulated norpropoxyphene complicates the early withdrawal period.
Opioid-specific support resources include SMART Recovery, Narcotics Anonymous, and medically assisted treatment programs. Given that dextropropoxyphene is no longer marketed, dependence today likely involves diverted or legacy supplies — disclosing this to a healthcare provider allows appropriate medical management without the complications of ongoing prescribing.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Blue or grey lips, slowed or stopped breathing, unresponsiveness, seizures, or collapse within minutes to one hour of ingestion. Unlike most opioid overdoses, cardiac arrest (not just respiratory failure) is a primary risk — the person may have a pulse but develop fatal irregular heart rhythm.
Immediate steps:
- 1. Call emergency services immediately — do not wait to see if they recover
- 2. Administer naloxone if available — it reverses respiratory depression but does NOT reverse cardiac toxicity[6]
- 3. Place in recovery position if breathing but unconscious
- 4. Begin CPR if no pulse or no breathing
- 5. Do NOT induce vomiting
What to tell the dispatcher: Name the substance (propoxyphene/Darvon/co-proxamol), approximate amount taken, time of ingestion, whether alcohol was involved, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from prosecution.
Reversal agents: Naloxone reverses opioid respiratory depression but has no effect on propoxyphene/norpropoxyphene cardiac toxicity. Cardiac toxicity requires hospital-level intervention (sodium bicarbonate for QRS widening, magnesium for QT prolongation). This distinction makes hospital transport essential even after naloxone administration.
Legal Status[edit]
Dextropropoxyphene has been withdrawn from pharmaceutical markets in all major jurisdictions. Its regulatory trajectory represents one of the most comprehensive post-marketing withdrawals of an analgesic, driven by evidence of a narrow therapeutic index, disproportionate overdose mortality, and cardiac toxicity at therapeutic doses. At the time of US withdrawal, it was classified as DEA Schedule IV.
| Jurisdiction | Status | Key provisions |
|---|---|---|
| United States | Withdrawn (November 19, 2010) | FDA requested voluntary market withdrawal citing QT prolongation at therapeutic doses; formerly DEA Schedule IV[10][12] |
| United Kingdom | Withdrawn (2005–2008) | CSM announced withdrawal January 2005; phased removal complete by 2008. Estimated 300–400 fewer overdose deaths per year[11] |
| European Union | Withdrawn (2008) | EMA recommended withdrawal of all marketing authorisations across member states |
| Ireland | Withdrawn (January 2006) | Distalgesic removed from Irish market[33] |
| Scotland | Withdrawn (2005–2008) | Followed UK CSM guidance; measurable reduction in poisoning deaths[34] |
| Australia | Cancelled from ARTG (~2010) | Dextropropoxyphene-containing products cancelled from Australian Register of Therapeutic Goods |
| India | Banned (2013) | Fixed-dose combinations banned by CDSCO |
| Canada | Status not confirmed | Regulatory status not verified in sources reviewedcitation needed |
Dextropropoxyphene remains available in some countries where regulatory withdrawal has not been implemented. Individuals encountering the substance today are likely obtaining diverted legacy stock or products from jurisdictions where it has not been fully removed. The drug's withdrawal history demonstrates that scheduling alone (Schedule IV at withdrawal) did not adequately control the public health risk of a widely prescribed analgesic with a narrow therapeutic index.
Frequently asked questions
What is Dextropropoxyphene?
Dextropropoxyphene is a synthetic opioid analgesic of the diphenylpropylamine class with low mu-opioid receptor affinity, marketed as Darvon from 1957. It was withdrawn globally by 2010 due to disproportionate overdose mortality and naloxone-insensitive cardiac toxicity from its metabolite norpropoxyphene.
How long does Dextropropoxyphene last?
Total duration by route of administration — Oral: 4 – 6 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Dextropropoxyphene?
Psychedex publishes a dosage table for Dextropropoxyphene on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Dextropropoxyphene?
The highest-severity documented interactions for Dextropropoxyphene: Benzodiazepines, Barbiturates (Lethal), GHB, Baclofen (Lethal), GHB, GBL (Lethal), Ibogaine (Lethal), Local anesthetics (Lethal). See the interactions section for the full list with mechanisms and severity levels.
Is Dextropropoxyphene addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Dextropropoxyphene: tolerance builds moderate; full reset takes 1.5 weeks; cross-tolerance develops with opioids. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2] ^abcLi Wan Po A, Zhang WY (1997) Systematic overview of co-proxamol to assess analgesic effects of addition of dextropropoxyphene to paracetamol — BMJ PMID:9437273
- [3] ^abcCollins GB, Kiefer KS (1981) Propoxyphene dependence: an update — Postgraduate Medicine PMID:7312731
- [4]
- [5]
- [6]
references
- [1] ^abVolpe DA, McMahon Tobin GA, Mellon RD, et al. (2011) Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs — Regulatory Toxicology and Pharmacology doi:10.1016/j.yrtph.2010.12.007
- [2]
- [3] ^abcLi Wan Po A, Zhang WY (1997) Systematic overview of co-proxamol to assess analgesic effects of addition of dextropropoxyphene to paracetamol — BMJ PMID:9437273
- [4] ^abcdCollins GB, Kiefer KS (1981) Propoxyphene dependence: an update — Postgraduate Medicine PMID:7312731
- [5]
- [6]